Skip to main content
OpenTrials
Completed

NCT Number: NCT02004327

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy

1. Primary

* AUClast, AUCinf, AUClast/D, AUCinf/D * Cmax, Cmax/D 2. Secondary

* Tmax, t1/2, CL/F, Vz/F 4. Safety

1. Adverse Event Monitoring 2. V/S, EKG, Laboratory Test, P/E

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Chonbuk National University Hospital

Jeonju-si, Jeollabuk-do, Geonjiro, Deokjin-gu, 561-712, South Korea

About this study

Healthy volunteers for clinical trials targeting drug administration date (1d) within 3 weeks from the (-21d ~-1d) in the interview, physical examination and laboratory tests , including through the screening is performed.

Through screening deems appropriate in this clinical trial is intended for the final subjects randomized to three groups to order .

The first phase one clinical trial subjects performed one day before (the -1 ) 18:00 Chonbuk National University Hospital, convened as a physical examination and perform hwalryeong signs .

One person to dinner , except for the drinking water should be fasting . One clinical trials (the first day) 20:00 subjects randomly assigned to groups according to the order in which the test is administered in a single oral medication .

The subjects for clinical trials with 240 mL water, medicines and swallow whole , chew before swallowing drugs should .

Blood according to the schedule after the clinical trial , including vital signs and physical examination is performed. The subjects that had a fixed schedule and is discharged on the morning of the second .

Is at least one week washout period . Since the two groups according to the order group and three creeping dose , except for the one the same tiles to proceed.

After a period of three clinical trials, three day period from taking drugs for clinical trials after 3-5 days to perform the post-study visit .

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • More than 20 years of age at the time of screening and less than 55 years old healthy male
  • (17.5 ~ 30.5 kg/m2 body mass index (BMI) and weight 45 kg or more

☞ body mass index (BMI) = weight (kg) / height (m) 2

  • No congenital or chronic diseases, internal medicine examination results who does not have psychotic symptoms or findings

Exclusion criteria

  • Clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but, at the time of administration of seasonal allergic untreated asymptomatic except for sex), medical history or evidence
  • Drugs that may affect the absorption of all the states (eg, gastrectomy)
  • Investigational drugs within two months before the first dose participated in other clinical trials

Treatment and study plan

DW1029M300mg

Drug

DW1029M300mg PO Once

Other names: DW1029M300mg 1 tablet

DW1029M600mg

Drug

DW1029M300mg 2 tablets Once

Other names: DW1029M300mg 2 tablets

DW1029M1200mg

Drug

DW1029M300mg 4 tablets PO Once

Other names: DW1029M300mg 4 tablets

Primary outcomes

  1. Maximum Concentration of DW1029M in plasma

    Time frame: 24 hours

Secondary outcomes

  1. Area under concentration-time curve of DW1029M in plasma

    Time frame: 24hours

  2. Time to maximal concentration of DW1029M in Plasma

    Time frame: 24hours

  3. Elimination half time of DW1029M in Plasma

    Time frame: 24hours

  4. Apparent clearance of DW1029M in Plasma

    Time frame: 24hours

  5. Apparent volume of distribution of DW1029M in Plasma

    Time frame: 24hours

Sponsors and collaborators

Lead sponsor

Dong Wha Pharmaceutical Co. Ltd.

Industry

Registry information

Official study title

Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer

Important dates

Study start
2013
Primary completion
2013
Study completion
2014
First posted
Dec 9, 2013
Registry last updated
Jun 29, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.